Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan
Cancer Medicine · 2024-09 · 13 (18)
DOI: 10.1002/cam4.70249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 24.09.2024. Verfasst von Kei Kunimasa und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Neoplasms, Precision Medicine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Comprehensive genome profiling (CGP) has revolutionized healthcare by offering personalized medicine opportunities. However, its real‐world utility and impact remain incompletely understood. This study examined the extent to which CGP leads to genomically matched therapy and its effectiveness.
Methods
We analyzed data from advanced solid tumor patients who underwent CGP panel between December 2019 and May 2023 at the Osaka International Cancer Institute. Patient demographics, specimen details, and expert panel assessments were collected. Turnaround time (TAT) and genomically matched therapy outcomes were analyzed. Gene alterations and their co‐occurrence patterns were also assessed.
Results
Among 1437 patients, 1096 results were available for analysis. The median TAT was 63 [28–182] days. There were 667 (60.9%) cases wherein recommended clinical trials were presented and there were 12 (1.1%) cases that could be enrolled in the trial and 25 (2.3%) cases that could lead to therapies under insurance reimbursement. The median progression free survival of the trial treatment was 1.58 months (95% CI: 0.66–4.37) in clinical trials and 3.66 months (95% CI: 2.14–7.13) in treatment under insurance. Pathologic germline variants were confirmed in 15 patients (1.3%). Co‐alteration of CDKN2A , CDKN2B , and MTAP was significantly observed in overall population.
Conclusion
The effectiveness of the genomically matched therapy based on the CGP panel was unsatisfactory. Expansion of clinical trials and utilization of remote clinical trials are required to ensure that the results of the CGP panel can be fully returned to patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Genetic Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Endocrinology and Metabolism, Clinical Laboratory, Osaka International Cancer Institute, Osaka, Japan.
- Laboratory of Genomic Pathology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Medical Oncology, Shiga General Hospital, Shiga, Japan.
ORCID-Profile: Kei Kunimasa, Toru Wakamatsu
Zitieren
APA
Kunimasa, K., Sugimoto, N., Yamasaki, T., Kukita, Y., Fujisawa, F., Inoue, T., Yamaguchi, Y., Kitasaka, M., Sakai, D., Honma, K., Wakamatsu, T., Yamamoto, S., Hayashi, T., Mabuchi, S., Okuno, J., Kawamura, T., Kai, Y., Urabe, M., & Nishimura, K. (2024). Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan. Cancer Medicine, 13(18). https://doi.org/10.1002/cam4.70249
Vancouver
Kunimasa K, Sugimoto N, Yamasaki T, Kukita Y, Fujisawa F, Inoue T, et al. Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan. Cancer Medicine. 2024;13(18). doi:10.1002/cam4.70249
BibTeX
@article{Kunimasa2024,
author = {Kunimasa, Kei and Sugimoto, Naotoshi and Yamasaki, Tomoyuki and Kukita, Yoji and Fujisawa, Fumie and Inoue, Tazuko and Yamaguchi, Yuko and Kitasaka, Mitsuko and Sakai, Daisuke and Honma, Keiichiro and Wakamatsu, Toru and Yamamoto, Sachiko and Hayashi, Takuji and Mabuchi, Seiji and Okuno, Jun and Kawamura, Takahisa and Kai, Yugo and Urabe, Makiko and Nishimura, Kazuo},
title = {Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {18},
doi = {10.1002/cam4.70249}
}
EUVIMED